U
ALXN

UBS’s Alexion Pharmaceuticals ALXN Stock Holding History

UBS’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$66K Hold
400
– – ﹤0.01% 6499
2014
Q2 		$63K Sell
400
-4,700
-92% -$742K ﹤0.01% 6559
2014
Q1 		$776K Buy
5,100
+4,700
+1,175% +$747K ﹤0.01% 3757
2013
Q4 		$53K Sell
400
-21,200
-98% -$2.54M ﹤0.01% 6887
2013
Q3 		$2.51M Sell
21,600
-24,000
-53% -$2.63M ﹤0.01% 2372
2013
Q2 		$4.21M Buy
+45,600
New +$4.39M 0.01% 1804

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS's ALXN Position: Q3 2014 in Review

UBS increased its Alexion Pharmaceuticals (ALXN) stake by 17% in Q3 2014, buying an estimated $3.23M and bringing the position to 132,425 shares worth $22M. The position accounts for 0.02% of the portfolio, ranked #900.

UBS first reported a position in ALXN in Q2 2013 and has held it in 6 quarters since. The position peaked at $30.5M in Q3 2013. 521 funds tracked by Wall St. Rank hold ALXN as of Q3 2014.

  • UBS held 132,425 shares of Alexion Pharmaceuticals worth $22M as of Q3 2014.
  • UBS bought 19,683 Alexion Pharmaceuticals shares in Q3 2014, an estimated $3.23M.
  • Alexion Pharmaceuticals made up 0.02% of UBS's portfolio in Q3 2014, its #900 holding.
  • UBS first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 6 quarters since.
  • UBS's Alexion Pharmaceuticals position peaked at $30.5M in Q3 2013.
  • 521 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.